Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer

AV Schally, AM Comaru-Schally, D. Gonzalez-Barcena

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

The methods for treatment of advanced prostate cancer, based on the agonistic analogs of LH-RH were reviewed. New therapeutic approaches utilizing antagonistic analogs of LH-RH such as SB-75 (Cetrorelix) have been described. Analogs of LH-RH chemically linked to various cytotoxic radicals are also being developed. Combinations of LH-RH agonists or antagonists with superactive somatostatin analogues such as Octastatin (RC-160) or with borobesin/GRP antagonists are being investigated in order to delay or prevent the relapse and improve the therapy for prostate cancer. LH-RH / analogs / prostate cancer.

Original languageEnglish (US)
Pages (from-to)465-471
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume46
Issue number10
DOIs
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer'. Together they form a unique fingerprint.

  • Cite this